Tag: Attralus

Attralus Presents New Data on Its Pan-Amyloid Diagnostic Candidates at the 2025 American College of Cardiology (ACC) Annual Scientific Session

Coronary/Structural Heart by Comments are Disabled

NAPLES, Fla., April 01, 2025 (GLOBE NEWSWIRE) — Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with systemic amyloidosis, announced three poster presentations (from four investigator-initiated trials), on the use of 124I-evuzamitide, the company’s pan-amyloid binding imaging agent in development for the diagnosis of cardiac amyloidosis, and one poster presentation of encouraging new clinical data from the University of Tennessee Graduate School of Medicine from an investigator-initiated trial on AT-05 (99mTc-p5+14) for the diagnosis of cardiac amyloid, at the 2025 American College of Cardiology (ACC) Annual Scientific Session held in Chicago, IL on March 29-April 1, 2025.

Continue Reading →

Attralus Receives Breakthrough Therapy Designation for its Pan-Amyloid Diagnostic PET Imaging Candidate 124I-evuzamitide (AT-01) for Cardiac Amyloidosis

Radiology by Comments are Disabled

BURLINGAME, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) — Attralus, Inc., a clinical stage biopharmaceutical company developing transformative products to improve the lives of patients with systemic amyloidosis, today announced that its investigational diagnostic imaging agent drug, 124I-evuzamitide (AT-01), has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for positron emission tomography (PET) imaging in patients with suspected or known cardiac amyloidosis. FDA granted BTD for 124I-evuzamitide (AT-01) based on clinical data from Attralus-sponsored and investigator-initiated studies evaluating the use of 124I-evuzamitide in patients with cardiac amyloidosis, representing experience in more than 200 trial participants.

Continue Reading →

Positive New Data from Phase 1/2 Trial of AT-01 Presented at 2022 American College of Cardiology Annual Scientific Session

Coronary/Structural Heart by 0 comments

AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of amyloid Sensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in AL Cardiac uptake was also observed in eleven patients who had not previously been diagnosed with cardiac disease SAN FRANCISCO, April […]

Continue Reading →

Attralus Announces Presentation of Clinical Data on AT-01, a Novel, Potential First-in-Class Diagnostic for Systemic Amyloidosis at the 2021 American College of Cardiology Annual Meeting

Coronary/Structural Heart by 0 comments

AT-01 detected cardiac amyloid in AL and ATTR patients with known cardiac disease with 95% sensitivity AT-01 detected cardiac amyloid in patients with AL or ATTR amyloid with normal levels of serum NT-proBNP AT-01 has the potential to distinguish AL and ATTR amyloidosis based on organ distribution SOUTH SAN FRANCISCO, […]

Continue Reading →